48. The antibody agent according to claim 46, wherein the substitute amino acid residue at position 60 is tryptophan.

49. The antibody agent according to claim 1, which is an IgG.

50. The antibody agent according to claim 1, which is a monoclonal antibody.

51. The antibody agent according to claim 1, wherein the antibody agent is selected from the group consisting of: a mouse antibody, humanized antibody, a human antibody, a purified antibody, an isolated antibody, a chimeric antibody, a polyclonal antibody, and combinations thereof.

52. The antibody agent according to claim 1, wherein the antibody agent is selected from the group consisting of: a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment, a Fd fragment, a Fd' fragment, a Fv fragment, a dAb fragment, a scFv fragment, an isolated CDR region, a dsFv diabody, a single chain antibody, and combinations thereof.

53. A cell line expressing an antibody agent according to claim 1.

54. A pharmaceutical composition comprising:
one or more antibody agents according to claim 1; and
a pharmaceutically acceptable carrier or excipient.

55. The pharmaceutical composition of claim 54, further comprising at least one additional antiviral agent.

56. ~~A method of treating a subject in need thereof, comprising administering~~Use of an antibody agent according to claim 1 in the manufacture of a medicament for treatment or prevention of Dengue virus infection in a subject in need thereof.